|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of the present study is to compare the predictive value of an LPA variant, rs10455872, as well as Lp(a) concentration on the prevalence of CVD and on the age of the first CVD event in a cohort of genetically confirmed heterozygous patients with familial hypercholesterolemia (FH).
|
31103339 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia.
|
31436336 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).
|
30846097 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Until last year, only the LDLR and LPA genes were appreciated as loci within which clinically relevant CNVs contributed to familial hypercholesterolemia and variation in Lp(a) levels, respectively.
|
30664016 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic traits for familial hypercholesterolemia and high lipoprotein(a) concentrations apparently co-exist and are associated with a higher ASVCD risk than each alone.
|
31393421 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low-density lipoprotein cholesterol (LDL-C) level and lipoprotein(a) [Lp(a)] ≥ 50 mg/dL predict atherosclerotic cardiovascular disease (ASCVD) risk in adults with familial hypercholesterolemia (FH), but their role for children with FH is less clear.
|
30150142 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objectives of this study are to investigate the association between rs2048327 and the prevalence of CVD as well as with the concentration of lipoprotein (a) (Lp (a)), in a cohort of genetically-confirmed heterozygous FH patients.
|
30772277 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
|
31683090 |
2019 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
|
28502508 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.
|
29480541 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirmed that the MFHS is a strong predictor of prevalent CVD in FH and that the addition of lipoprotein(a) offers a minor improvement in the discrimination of the score.
|
28801029 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent literature involving CNVs and dyslipidemias has focused mainly on rare CNVs causing familial hypercholesterolemia, and a common CNV polymorphism as the major determinant of lipoprotein(a) plasma concentrations.
|
29303791 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to investigate the relation between lipoprotein(a) [Lp(a)] and proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations, and their complex, in patients with potential familial hypercholesterolemia (FH), depending on apo(a) phenotype.
|
30270088 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relation of lipoprotein (a) [Lp(a)] and proprotein convertase substilisin/kexin type 9 (PCSK9) levels to coronary artery disease (CAD) has been well established in the general population, while little is known about the association between Lp(a) or PCSK9 and atherosclerotic lesions of different artery sites in patients with familial hypercholesterolemia (FH).
|
30170223 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.
|
29603377 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the associations of lipoprotein (a) [Lp(a)] with the FH phenotype, genotype and roles of Lp(a) in determining CAD risk among patients with and without FH.
|
28351002 |
2017 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).
|
29096862 |
2017 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing attention has come upon the genetic disorders of familial hypercholesterolemia and elevated lipoprotein(a).
|
28429242 |
2017 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
|
26632531 |
2016 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
|
27594539 |
2016 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship between LDLR genotype and the plasma levels of PCSK9, LDL-C, and lipoprotein (a) (Lp(a)) in a large cohort of genetically defined FH heterozygotes (HeFH).
|
26371983 |
2015 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear.
|
26340131 |
2015 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 and 3 clinical trials in patients with moderate and severe hypercholesterolemia (including FH) show that this approach is safe and highly efficacious to lower LDL-C and lipoprotein(a).
|
25248569 |
2014 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.
|
24632281 |
2014 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Total cholesterol and lipoprotein (a) were increased in FH children compared to controls (282.3+/-8.8 mg/dl vs. 163.8+/-4.6 mg/dl and 11.0[4.6, 30.7]mg/dl vs. 5.24[2.63, 11.0]mg/dl median [IQR] respectively; p<0.001 for both).
|
19004443 |
2009 |